Drug regimens in patients with medication-resistant epilepsy in neurology and epilepsy outpatient departments in Spain;Pautas terapéuticas en el paciente con epilepsia farmacorresistente en consultas ambulatorias de neurología y epilepsia en España

Revista de Neurologia

Volumn 47, Issue 10, 2008, Pages 517-524

  Rufo Campos, Miguel ^a   Sancho Rieger, J ^b   Pena P ^c   Masramon, X ^d   Rejas Gutierrez J ^e  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d European Biometrics Institute   (Spain)

^e PFIZER INC   (United States)

Author keywords

Antiepileptic drugs; Efficacy; LINCE study; Prevalence; Refractory epilepsy

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PREGABALIN; TOPIRAMATE;

ACADEMIC ACHIEVEMENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG COMBINATION; EMPLOYEE; EPILEPSY; FEMALE; HEALTH CARE COST; HUMAN; MALE; PREVALENCE; QUALITY OF LIFE; SEX DIFFERENCE; SPAIN;

EID: 57049105745     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4710.2008409     Document Type: Article

References (56)

1. Forsgren L, Beghi E, Oun A, Sillanpaa M. The epidemiology of epilepsy in Europe -a systematic review. Eur J Neurol 2005; 12: 245-53.
2. Nieto-Barrera M. Neuroepidemiology of epilepsies. An Esp Pediatr 1988; 29 (Suppl) 33: S59-63.
3. Ochoa-Sangrador C, Palencia Luaces R. Study of the prevalence of epilepsy among schoolchildren in Valladolid, Spain. Epilepsia 1991; 32: 791-7.
4. López-Pisón J, Arana T, Abenia P, Galván M, Muñoz-Albillos M, Peña-Segura JL. Casuística de epilepsias idiopáticas y criptogénicas en una unidad de neuropediatría de referencia regional. Rev Neurol 2000; 31: 733-8.
5. Durá-Travé T, Yoldi-Petri ME. Epilepsy and epileptic syndromes among primary school children (6-12 years). An Pediatr (Barc) 2007; 66: 11-6.
6. Saiz-Díaz R. Antiepilépticos: aportación de los nuevos fármacos. Inf Ter Sist Nac Salud 2004; 28: 33-40.
7. Kotsopoulos IA, Van Merode T, Kessels FG, De Krom MC, Knottnerus JA. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002; 43: 1402-9.
8. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995; 346: 140-4.
9. Lindsten H, Stenlund H, Forsgren L. Remission of seizures in a population-based adult cohort with a newly diagnosed unprovoked epileptic seizure. Epilepsia 2001; 42: 1025-30.
10. Shafer SQ, Hauser WA, Annegers JF, Klass DW. EEG and other early predictors of epilepsy remission: a community study. Epilepsia 1988; 29: 590-600.
11. Cockerell OC, Johnson AL, Sander JW, Shorvon SD. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997; 38: 31-46.
12. Placencia M, Sander JW, Roman M, Madera A, Crespo F, Cascante S, et al. The characteristics of epilepsy in a largely untreated population in rural Ecuador. J Neurol Neurosurg Psychiatry 1994; 57: 320-5.
13. Wang WZ, Wu JZ, Wang DS, Dai XY, Yang B, Wang TP, et al. The prevalence and treatment gap in epilepsy in China: an ILAE/IBE/WHO study. Neurology 2003; 60: 1544-5.
14. Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 2004; 75: 1376-81.
15. Arroyo S, Brodie MJ, Avanzini G, Baumgartner C, Chiron C, Dulac O, et al. Is refractory epilepsy preventable? Epilepsia 2002; 43: 437-44.
16. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979; 20: 729-37.
17. Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Collaborative Group for the Study of Epilepsy. Epilepsia 1992; 33: 45-51.
18. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.
19. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58: S2-8.
20. Gómez-Alonso J, Giráldez BG. Epilepsia: una nueva definición para una vieja enfermedad. Rev Neurol 2007; 45: 126-7.
21. Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia 2006; 47: 431-6.
22. Sánchez-Álvarez JC, Serrano-Castro P, Cañadillas- Hidalgo F. Epilepsia refractaria del adulto. Rev Neurol 2002; 35: 931-53.
23. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30: 389-99.
24. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42: 796-803.
25. Engel J Jr. Intractable epilepsy: definition and neurobiology. Epilepsia 2001; 42 (Suppl 6): S3.
26. Sabaz M, Cairns DR, Lawson JA, Bleasel AF, Bye AM. The health-related quality of life of children with refractory epilepsy: a comparison of those with and without intellectual disability. Epilepsia 2001; 42: 621-8.
27. Tetto A, Manzoni P, Millul A, Beghi E, Garattini L, Tartara A, et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 2002; 48: 207-16.
28. Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004; 45: 171-8.
29. Sancho J, Peña P, Rufo M, Palacios G, Masramón X, Rejas J. LINCE Study Collaborative Group. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of-illness Study (LINCE study). Epilepsy Res 2008; doi: 10.1016/j.eplepsyres.2008.05.008.
30. Brodie MJ. Diagnosing and predicting refractory epilepsy. Acta Neurol Scand Suppl 2005; 181: 6-39.
31. Brodie MJ, Shorvon SD, Canger R, Halasz P, Johannessen S, Thompson P, et al. Commission on European Affairs: appropriate standards of epilepsy care across Europe. ILEA. Epilepsia 1997; 38: 1245-50.
32. Provision of care. Epilepsia 2003; 44: 39-40.
33. Brodie MJ. Medical therapy of epilepsy: when to initiate treatment and when to combine? J Neurol 2005; 252: 125-30.
34. Deckers CL, Knoester PD, De Haan GJ, Keyser A, Renier WO, Hekster YA. Selection criteria for the clinical use of the newer antiepileptic drugs. CNS Drugs 2003; 17: 405-21.
35. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45: 20-7.
36. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291: 605-14.
37. Herranz JL. Farmacogenética, farmacogenómica y terapia antiepiléptica individualizada. Rev Neurol 2006; 43 (Supl 1): S43-9.
38. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261-73.
39. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002; 48: 206-8.
40. Hermann B, Jones J, Sheth R, Dow C, Koehn M, Seidenberg M. Children with new-onset epilepsy: neuropsychological status and brain structure. Brain 2006; 129: 2609-19.
41. McNelis AM, Dunn DW, Johnson CS, Austin JK, Perkins SM. Academic performance in children with new-onset seizures and asthma: a prospective study. Epilepsy Behav 2007; 10: 311-8.
42. Hermann B, Jones J, Dabbs K, Allen CA, Sheth R, Fine J, et al. The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy. Brain 2007; 130: 3135-48.
43. Ibekwe RC, Ojinnaka NC, Iloeje SO. Factors influencing the academic performance of school children with epilepsy. J Trop Pediatr 2007; 53: 338-43.
44. Fonseca LC, Tedrus GM, Pacheco EM, Berretta MF, Campregher AA, Costa DM. Benign childhood epilepsy with centro-temporal spikes: correlation between clinical, cognitive and EEG aspects. Arq Neuropsiquiatr 2007; 65: 569-75.
45. Falip M, Artazcoz L, De la Peña P, Pérez-Sempere A, Codina M. Clinical characteristics associated with psychosocial functioning among patients with uncomplicated epilepsy in Spain. Seizure 2007; 16: 195-203.
46. Hart YM, Shorvon SD. The nature of epilepsy in the general population. I. Characteristics of patients receiving medication for epilepsy. Epilepsy Res 1995; 21: 43-9.
47. Koponen A, Seppala U, Eriksson K, Nieminen P, Uutela A, Sillanpaa M, et al. Social functioning and psychological well-being of 347 young adults with epilepsy only -population-based, controlled study from Finland. Epilepsia 2007; 48: 907-12.
48. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-120.
49. Landmark CJ, Rytter E, Johannessen SI. Clinical use of antiepileptic drugs at a referral centre for epilepsy. Seizure 2007; 16: 356-64.
50. 2δ de canales de calcio en el tratamiento de la epilepsia y el dolor neuropático. Rev Neurol 2006; 42: 223-37.
51. Herranz JL, Prats-Viñas JM, Campistol J, Campos-Castelló J, Rufo-Campos M, Casas-Fernández M, et al. Eficacia y tolerabilidad del levetiracetam en 133 niños con crisis epilépticas farmacorresistentes. Rev Neurol 2006; 43: 393-7.
52. Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of addon therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia 2008; 49: 431-7.
53. Díaz S, Argumosa A, Horga de la Parte JF, Vera-Llonch M, Dukes E, Rejas-Gutiérrez J. Análisis coste-efectividad del tratamiento de la epilepsia parcial refractaria: un modelo de simulación de pregabalina y levetiracetam. Rev Neurol 2007; 45: 460-7.
54. Corredera-García E, Gómez-Alonso J, Arias M, Seijo-Martínez M, Rodríguez J, Rubio-Nazábal E, et al. Tratamiento con topiramato en pacientes con epilepsia refractaria. Rev Neurol 2003; 37: 401-4.
55. Carreno M, Maestro I, Molins A, Donaire A, Falip M, Becerra JL, et al. Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice. Seizure 2007; 16: 709-12.
56. Cates ME, Feldman JM, Boggs AA, Woolley TW, Whaley NP. Efficacy of add-on topiramate therapy in psychiatric patients with weight gain. Ann Pharmacother 2008; 42: 505-10.